Founded in Lexington, Kentucky, Nexosome Oncology is dedicated to revolutionizing cancer detection through the application of exosome-based diagnostics. Their core mission is to enhance early cancer detection and patient care by leveraging plasma proteomics to identify unique biomarkers. Nexosome Oncology offers highly accurate and reproducible liquid biopsy tests that eliminate the need for invasive tissue biopsies, achieving over 90% accuracy in multiple cancer indications.
Notable figures affiliated with Nexosome Oncology include leading oncologists and researchers in the field of exosome diagnostics. The company has attracted significant investment from healthcare-focused venture capital firms, underscoring its potential impact. Key achievements include identifying approximately 2,000 proteins that provide unique insights into tumor biology and patient responses. Nexosome Oncology's innovative approach has the potential to significantly improve early cancer detection and patient outcomes globally.
